Disease Markers / 2019 / Article / Tab 1

Research Article

Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma

Table 1

Patients’ characteristics () and their association with serum MMP9 before treatment.

Characteristic (%)MMP9 before treatment (ng/ml)
Median (25%-75%)

GenderMale89 (80.9)707.8 (502.3-1224.7)0.651a
Female21 (19.1)683.5 (404.1-1231.8)

AgeMedian (25%-75%) (years)66 (59.8-72.3)Spearman’s 0.410b

StageI12 (10.9)595.8 (502.6-1412.1)0.982a
II22 (20.0)729.0 (396.8-1216.0)
III42 (38.2)772.3 (452.6-1277.5)
IV27 (24.5)698.5 (548.9-1207.2)
Peritoneal7 (6.4)757.4 (632.5-1511.6)

Histological typeEpithelioid81 (73.6)757.4 (497.6-1213.2)0.830a
Biphasic15 (13.6)683.5 (393.3-1408.9)
Sarcomatoid11 (810.0)641.3 (483.4-1178.1)
Not characterized3 (2.7)705.7 (698.5-705.7)

ECOG performance status013 (11.8)466.7 (383.2-842.5)0.010a
156 (50.9)682.0 (431.5-1088.4)
241 (37.3)1026.5 (579.9-1443.0)

CRPMedian (25%-75%) (mg/l)17.5 (6.3-54.3) [6]Spearman’s 0.498b

LDHMedian (25%-75%) (μkat/l)2.6 (2.2-2.9) [6]Spearman’s 0.505b

Asbestos exposureNot exposed24 (21.8)644.1 (502.6-1238.1)0.625a
Exposed86 (78.2)749.1 (497.1-1216.0)

SmokingNonsmokers61 (56.0) [1]707.8 (406.6-1293.5)0.732a
Smokers48 (44.0)687.7 (558.0-1199.9)

PainNo50 (45.9) [1]641.3 (497.1-1243.9)0.349a
Yes59 (54.1)800.2 (546.1-1242.3)

Weight lossNo32 (29.6) [2]868.9 (567.9-1175.4)0.699a
Yes76 (70.4)682.0 (485.9-1357.7)

Numbers in [] denote missing data. aCalculated using the Mann-Whitney or Kruskal-Wallis test. bCalculated using Spearman’s rho. CRP: C-reactive protein; ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.